Nanoscope Therapeutics publishes study on functional vision assessment
Nanoscope Therapeutics has published a peer-reviewed observational study in Documenta Ophthalmologica, focusing on performance-based measures for assessing vision changes in patients with severe retinal diseases. The study involved 35 subjects, including 25 with severe vision loss from retinitis pigmentosa, and evaluated the Multi-luminance Shape Discrimination Test (MLSDT) for its reliability and validity as a functional vision measure. Notably, the RESTORE Phase 2b/3 trial of Nanoscope’s lead therapy, MCO-010, utilized MLSDT as a secondary endpoint, revealing that most treated patients achieved significant improvements in vision after one year.
This research is crucial for the longevity and healthspan fields as it highlights the potential of MCO-010 to offer clinically meaningful benefits for patients suffering from severe vision loss, a condition that significantly impacts quality of life. Nanoscope is advancing its regulatory strategy with a rolling BLA submission to the FDA and plans for a Phase 3 trial in 2026, reflecting a commitment to bringing innovative therapies to market.
For professionals in the longevity sector, this study underscores the importance of functional vision assessments in clinical trials and the potential for novel therapies to enhance healthspan by addressing debilitating conditions like retinitis pigmentosa.